Please use this identifier to cite or link to this item: https://doi.org/10.1345/aph.1D153
DC FieldValue
dc.titleOxaliplatin/Fluorouracil/Leucovorin in Advanced Colorectal Carcinoma: An Asian Experience
dc.contributor.authorLim, E.H.
dc.contributor.authorLim, R.S.C.
dc.contributor.authorWu, T.S.
dc.contributor.authorKong, H.L.
dc.date.accessioned2016-11-28T10:17:35Z
dc.date.available2016-11-28T10:17:35Z
dc.date.issued2003-12
dc.identifier.citationLim, E.H., Lim, R.S.C., Wu, T.S., Kong, H.L. (2003-12). Oxaliplatin/Fluorouracil/Leucovorin in Advanced Colorectal Carcinoma: An Asian Experience. Annals of Pharmacotherapy 37 (12) : 1909-1912. ScholarBank@NUS Repository. https://doi.org/10.1345/aph.1D153
dc.identifier.issn10600280
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/131217
dc.description.abstractBACKGROUND: Oxaliplatin/fluorouracil/leucovorin (FOLFOX4) is an effective and generally well-tolerated regimen in Western studies of metastatic colorectal carcinoma. OBJECTIVE: To evaluate the objective tumor responses and toxicities of the FOLFOX4 regimen in a predominantly Chinese population with advanced colorectal carcinoma in Singapore. METHODS: Forty-seven consecutive patients were enrolled in a retrospective study between March 1998 and December 2001. FOLFOX4 was first-line treatment in 36% of these patients, second-line in 36%, third-line in 17%, and fourth-line in 11%. Tumor responses were assessed radiologically, and toxicities were graded by the National Cancer Institute common toxicity system. RESULTS: The objective response rate (all partial responses) was 45%, and stable disease was achieved in 35% of the patients. There were no deaths due to toxicity. Mild to moderate peripheral sensory neuropathy affected half of the patients, with 1 report of cold exacerbation in this tropical series. The rate of hypersensitivity reactions to oxaliplatin was 11%, and they usually occurred late in the treatment course. CONCLUSIONS: FOLFOX4 has good efficacy in metastatic colorectal carcinoma in our local population, but the rate of hypersensitivity reactions to oxaliplatin was high.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1345/aph.1D153
dc.sourceScopus
dc.subjectAsian
dc.subjectColorectal carcinoma
dc.subjectHypersensitivity
dc.subjectOxaliplatin
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1345/aph.1D153
dc.description.sourcetitleAnnals of Pharmacotherapy
dc.description.volume37
dc.description.issue12
dc.description.page1909-1912
dc.description.codenAPHRE
dc.identifier.isiut000186795300027
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.